J. Molner AS Group (hereinafter the Company) on 1 June 2026 signed and completed the acquisition of a portfolio of US-marketed generic and specialty pharmaceutical products from Nordic Pharma, Inc. (the Seller).
The acquired business comprises 13 product registrations approved by the U.S. Food and Drug Administration (FDA) across four therapeutic categories: critical care, ophthalmology, specialty oral products, and haematology/oncology. In addition to the product registrations, the acquired portfolio includes related intellectual property, trademarks, regulatory dossiers, customer relationships, and other assets required for the operation of the business. J. Molner has also assumed customary post-sale obligations associated with the portfolio, including standard channel and payer pricing adjustments (chargebacks, rebates, returns, and similar mechanisms).
The portfolio has a long-established commercial presence in the United States. The acquisition strengthens J. Molner’s footprint in US hospital, specialty pharmacy, and retail pharmacy channels and broadens the therapeutic categories it serves. The transaction is expected to have a significant impact on J. Molner’s asset base and to expand the Company’s US commercial revenue base. The precise extent of the transaction’s impact cannot be reliably determined at this time. The financial terms of the transaction are commercially confidential.
Following the completion of the transaction, Nordic Pharma, Inc. will provide transitional services to J. Molner for an agreed period, covering regulatory affairs, quality management, supply chain, and commercial operations, in order to ensure uninterrupted supply to customers and a seamless integration of the acquired business into J. Molner’s US operating platform.
Raymond James acted as exclusive financial advisor to Nordic Pharma, Inc. in connection with the transaction.
For further information, please contact:
Sten Akel
J. Molner AS
CFO
+372 550 5259
s.akel@jmolner.com